Acessibilidade / Reportar erro

Babesia divergens vaccine

Abstract

A vaccine strategy against Babesia divergens bovine babesiosis was sucessfully developed after perfecting of an efficient in vitro culture. Crude supernatants and purified fractions were able to induce a vaccine protection in gerbils against B. divergens infection. More, supernatants induced an effective vaccine protection in cattle. The role of B. divergens exoantigens of 17, 37, 46, 70 and 90 kDa in the development of the immune response was cleary demonstrated in gerbils, cattle, and man.

Babesia divergens; in vitro culture; exoatingen; vaccine


ABSTRACT

Babesia divergens vaccine

A. Gorenflot1

E. Precigout2

A. Valentin3

G. Bissuel4

B. Carcy1

P. Brasseur5

Y. Moreau4

J. Schrevel1

Faculté de Pharmacie, Laboratoire de Biologie Cellulaire, Montpellier, France

URA CNRS 290, Laboratoire de Biologie Cellulaire, Poitiers, France

URA CNRS 290, Laboratoire de Biologie Cellulaire, Lyon, France

Laboratoire IFFA, Lyon, France

Hôtel Dieu, Laboratoire de Parasitologie, Rouen, France

A vaccine strategy against Babesia divergens bovine babesiosis was sucessfully developed after perfecting of an efficient in vitro culture. Crude supernatants and purified fractions were able to induce a vaccine protection in gerbils against B. divergens infection. More, supernatants induced an effective vaccine protection in cattle. The role of B. divergens exoantigens of 17, 37, 46, 70 and 90 kDa in the development of the immune response was cleary demonstrated in gerbils, cattle, and man.

Full text available only in PDF format.

Texto completo disponível apenas em PDF.

Publication Dates

  • Publication in this collection
    04 June 2009
  • Date of issue
    1992
Instituto Oswaldo Cruz, Ministério da Saúde Av. Brasil, 4365 - Pavilhão Mourisco, Manguinhos, 21040-900 Rio de Janeiro RJ Brazil, Tel.: (55 21) 2562-1222, Fax: (55 21) 2562 1220 - Rio de Janeiro - RJ - Brazil
E-mail: memorias@fiocruz.br